BioWorld

Feb. 8, 2007

BioLineRx Prices $50M IPO, Listing On Tel Aviv Exchange

Israeli drug development firm BioLineRx Ltd. gained a listing on the Tel Aviv Stock Exchange and brought in $50 million in an oversubscribed initial public offering. (BioWorld Today) Read More

Proacta Completes $35M Series B For Hypoxia Trials

Encysive Sells $60M In Notes Secured By Argatroban Royalties

Biogen Idec Testing Targeted MAB In Pivotal CLL Study

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...